Introduction
Glucokinase (GCK), an enzyme phosphorylating glucose to glucose-6-phosphate, acts as a glucose sensor and regulates insulin secretion
. GLUT2 is an important component for insulin secretion as well [15, 16] . Tiedge and Lenzen reported in their studies that the concordant regulation of GCK and GLUT2 genes might represent the basis regulation of GSIS [17] . In 2006, Yang et al. firstly reported that leucine culture altered GCK expression in INS-1 cells, rat islets and human islets, moreover, GCK contributed tight control of insulin secretion [1] .
Though AMPK, GCK and GLUT2 were separately reported to be associated with insulin secretion, the relationship between them under leucine exposure remains unclear. Kim et al. demonstrated that AMPK could regulate GCK and GLUT2 expression at high glucose concentration [18] . On the basis of these reports, we supposed that chronic leucine exposure might influence insulin secretion and content by altering AMPK, GCK and GLUT2 expression, and there might be a regulatory relationship between AMPK, GCK and GLUT2 at high leucine concentrations. In addition, how AMPK regulates GCK or GLUT2 was worthy of being investigated. [19] [20] [21] [22] . The role of PDX-1 in pancreatic ␤-cell insulin secretion [23] [24] [25] derives from its effect on transactivating the expression of insulin and other ␤-cell-specific genes, such as GCK and GLUT2 [26] [27] [28] [29] . This promoted us to speculate that PDX-1 might be the bridge between AMPK and GCK or GLUT2. were grown in monolayer culture in Roswell Park Memorial Institute (RPMI) 1640 medium (without glutamine) containing 11.1 mM glucose supplemented with 10 mM HEPES, 10% (v/v) foetal bovine serum (Invitrogen, NY, USA), 1 mM sodium pyruvate, 50 M ␤-mercaptoethanol, 100 IU/ml penicillin and 100 g/ml streptomycin at 37ЊC in an humidified atmosphere with 5% CO2 and 95% air [28, 30] . The [33] . In the study, the cells were firstly treated with or without 500 ng/ml doxycycline for the indicated time (24, 48 and 72 hrs) . Then, the cells were treated with either 0.5 mM AICAR or 10 M compound C for 48 hrs. Fig. 1D (Fig. 3B) (Fig. 3C) as well. Fig. 4A (Fig. 4C , P Ͼ 0.05) and RIN m5F cells (Fig. 4D, P Ͼ 0.05) . The results above were confirmed by real-time PCR (Fig. 4E and F Fig. 6D1) and RIN m5F cells (Fig. 6D2) . Fig. 7A1, P Ͻ 0.05) , decreased intracellular insulin content by 23% and 62% (Fig.7A2, P Ͻ 0.05) , respectively. In comparison with leucine treatment alone group, doxycycline plus leucine treatment decreased high glucose-induced insulin secretion by 67% (Fig. 7A1 , P Ͻ 0.05) and intracellular insulin content by 44% (Fig. 7A2, P Ͻ 0.05) . In PDX-1#6 cells, compared with control, leucine alone treatment diminished high glucose-induced insulin secretion by 26% (Fig. 7C1 , P Ͻ 0.05) and insulin content by 25% (Fig. 7C2, P Ͻ 0.05) , doxycycline alone treatment increased high glucose-induced insulin secretion by 20% (Fig. 7C1 , P Ͻ 0.05) and insulin content by 21% (Fig. 7C2, P Ͻ 0.05) . However, relative to leucine alone treatment, doxycycline plus leucine treatment significantly increased GSIS by 36% (Fig. 7C1 , P Ͻ 0.05) and insulin content by 21% (Fig. 7C2, P Ͻ 0.05) . The results were confirmed by real-time in DN-PDX-1#28 cells (Fig. 7B) and PDX-1#6 cells (Fig. 7D) as well.
Numerous studies in vitro and in vivo have demonstrated that chronic exposure to glucose or fatty acid is able to suppress pancreatic/duodenal homeobox-1 (PDX-1) expression, leading to decreased insulin secretion

Collectively, from these findings, we suggested that there might be a regulatory link between AMPK and PDX-1 in pancreatic ␤-cells exposed to leucine, in turn to affect insulin secretion and content. To test the hypothesis, we firstly examined if the regulation existed under relative physiological condition. Then, we tested the effects of elevated concentrations of leucine on insulin secretion, insulin content and the protein expression of p-AMPK, PDX-1, GCK and GLUT2. Finally, we investigated if chronic leucine exposure influenced insulin secretion and content associated with the assumed regulation (AMPK regulates GCK and GLUT2 via PDX-1).
Research design and methods
Cell culture and treatment
Rat insulinoma (RIN) cell lines, INS-1 and RIN m5F cells (passage
Insulin secretion and insulin content assays
mM glucose () in INS-1 cells and intracellular insulin content (B) in INS-1 cells and RIN m5F cells were determined by radioimmunoassay. The values were normalized by the intracellular protein content. The effects of AICAR or compound C on PDX-1, GCK and GLUT2 protein expression was tested by Western blotting in INS-1 cells (C) and RIN m5F cells (D). The mRNA expression of PDX-1, GCK and GLUT2 in INS-1 cells (E) and RIN m5F cells (F) was
The effects of elevated concentrations of leucine in INS-1 and RIN m5F cells
To obtain insight into the functional changes when exposed to elevated concentrations of leucine, INS-1 and RIN m5F cells were cultured with or without elevated levels of leucine for 48 hrs. The cells were then used to determine insulin secretion as well as intracellular insulin content. As shown in
Moreover, in comparison with leucine treatment, leucine plus AICAR co-treatment diminished high glucose-induced insulin secretion by
Fig. 3 Neither AICAR nor compound C could affect GCK and GLUT2 expression when PDX-1 expression was absent. DN-PDX-1#28 cells were pre-treated with or without 500 ng/ml doxycycline for 24 hrs prior to treatment with or without 0.5 mM AICAR or 10 M compound C for a further 48 hrs. Insulin secretion (A1) at 3 mM glucose (ᮀ) and 27.8 mM glucose () and insulin content (A2) were determined by radioimmunoassay. The values were normalized by the intracellular protein content. The PDX-1, GCK and GLUT2 protein and mRNA expression were determined by Western blotting (B) and real-time PCR (C)
.
21% in INS-1 cells (Fig. 6A1, P Ͻ 0.05) and intracellular insulin content by 23% in INS-1 cells (Fig. 6A2, P Ͻ 0.05), and 26% in RIN m5F cells (Fig. 6B, P Ͻ 0.05). Furthermore, the reduced insulin secretion and content caused by chronic high leucine treatment were significantly recovered by leucine plus compound C co-treatment. In contrast to leucine treatment, leucine plus compound C cotreatment increased high glucose-induced insulin secretion by 33% in INS-1 cells (Fig. 6A1, P Ͻ 0.05) and intracellular insulin content by 24% in INS-1 cells (Fig. 6A2, P Ͻ 0.05) and 29% in RIN m5F cells (Fig. 6B, P Ͻ 0.05), respectively. Neither AICAR nor compound C produced significant difference at low glucose stimulation in comparison with control in INS-1 cells (Fig. 6A1, P Ͼ 0.05).
In order to further determine whether AMPK regulated PDX-1 under chronic high leucine exposure, Western blotting and realtime PCR were performed in INS-1 and RIN m5F cells. The weak bands representing protein expression of PDX-1, GCK and GLUT2, respectively, appeared in 40 mM leucine alone and AICAR alone groups, and the weakest band occurred in 40 mM leucine plus AICAR co-treatment group compared with control (Fig. 6C, P Ͻ 0.05). The reduced protein expression of PDX-1, GCK and GLUT2 induced by chronic high leucine was recovered almost to normal in leucine plus compound C co-treatment group (Fig. 6C, P Ͻ 0.05). The results were confirmed by real-time PCR in both INS-1 (
Fig. 4 The effects of elevated concentrations of leucine in ␤-cells. INS-1 and RIN m5F cells were treated with or without elevated concentrations of leucine (10, 20 or 40 mM) for 48 hrs. Insulin secretion (A) at 3 mM glucose (ᮀ) and 27.8 mM glucose () in INS-1 cells and intracellular insulin content in INS-1 (B) and RIN m5F cells (B) were determined by radioimmunoassay. The values were adjusted by the intracellular protein content. The protein expression of p-AMPK, PDX-1, GCK and GLUT2 in INS-1 cells (C) and RIN m5F cells (D) was detected by Western blotting. The mRNA expression of PDX-1, GCK and GLUT2 in INS-1 cells (E) and RIN m5F cells (F) was tested using real-time PCR. The data are the means Ϯ S.D. The results
The effects of leucine in DN-PDX-1#28 and PDX-1#6 ␤-cells
To further prove that the PDX-1 plays an important role in impaired insulin secretion and content induced by chronic leucine, DN-PDX-1#28 and PDX-1#6 cells were treated with or without 500 ng/ml doxycycline, in the presence or absence of 40 mM leucine for 48 hrs. In DN-PDX-1#28 cells, in comparison with control, leucine alone treatment and doxycycline alone treatment diminished high glucose-induced insulin secretion by 36% and 84% (
Discussion
In the present study, we found firstly that PDX-1, which activated GCK and GLUT2, was a possible target for AMPK action in INS-1 and RIN m5F cells. AMPK activation induced by AICAR, a AMPK agonist, might result in decreased intracellular insulin content in ␤-cells; as a result, high glucose-induced insulin secretion decreased. We also demonstrated that AICAR enhanced chronic high leucine-induced reduction of insulin secretion and content by down-regulating PDX-1, GCK and GLUT2 expression. Finally, we reconfirmed our results in both DN-PDX-1#28 and PDX-1#6 cells that the inhibition of PDX-1 could potentiate the impaired effects induced by leucine and overexpression of PDX-1 could protect the cell from impairment induced by leucine.
We did not use pancreatic islets because we encountered many difficulties, including the preparation of large numbers of viable islets and cellular heterogeneity as in the previous reports [34] . In addition, our aim in the present study focused on effects of leucine on the ␤-cells. [40] [41] [42] . RIN m5F cells can also secrete detectable amounts of insulin [34, 43] . Moreover, the two cell lines maintain a stable balance of insulin secretion under physiological condition [44] . Furthermore, the responsiveness of the cell lines is almost equal to that of islet and they can be kept with fuction in culture media for cumulative periods [34] . Insulin content is contributed to by varying rates of proinsulin synthesis and processing, insulin secretion and intracellular insulin degradation. Under normal circumstances, in primary ␤-cells, insulin content stays constant. Either leucine or AICAR has been reported to be able to affect insulin secretion and insulin content [1, 6, 18] , which were partially in agreement with our results.
The present study reports the role of AMPK activation on insulin secretion and intracellular insulin content; moreover, it proposes that AMPK regulates GCK and GLUT2 under relative physiological condition. Recently, a number of studies have reported that AMPK activation exerts inhibitory effects on insulin secretion and content in vitro and in vivo [18, [45] [46] [47] [26] [27] [28] [29] . In DN-PDX-1#28 cells, we found that PDX-1 positively regulated GCK and GLUT2, which were in accordance with the reports from the previous studies [33] . [14, 18, [45] [46] [47] . In the present study, our investigation showed that 40 mM leucine significantly enhanced p-AMPK protein expression. PDX-1, GCK and GLUT2 were reported to be positively correlated with insulin secretion by different mechanisms [1, 17, 25, 26] 
